Astria Therapeutics Inc (ATXS) — Cash Flow-to-Debt Ratio
Astria Therapeutics Inc (ATXS) has a Cash Flow-to-Debt Ratio of -0.84x as of September 2025, meaning its operating cash flow of $-32.30 Million could theoretically repay -1% of its total liabilities ($38.61 Million) in one year. See ATXS net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Astria Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Astria Therapeutics Inc across 13 annual periods. Also explore ATXS net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Astria Therapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Astria Therapeutics Inc. For market capitalisation and broader financial context, see ATXS company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.52x | $-81.21 Million | $23.10 Million | ▲ +40.7% |
| 2023 | -5.93x | $-68.44 Million | $11.55 Million | ▼ -28.2% |
| 2022 | -4.62x | $-43.53 Million | $9.42 Million | ▲ +20.2% |
| 2021 | -5.79x | $-30.15 Million | $5.20 Million | ▼ -21.1% |
| 2020 | -4.79x | $-32.48 Million | $6.79 Million | ▼ -9.2% |
| 2019 | -4.38x | $-26.57 Million | $6.06 Million | ▲ +21.0% |
| 2018 | -5.55x | $-23.46 Million | $4.23 Million | ▼ -26.3% |
| 2017 | -4.40x | $-26.84 Million | $6.11 Million | ▼ -48.8% |
| 2016 | -2.95x | $-32.86 Million | $11.12 Million | ▼ -36.1% |
| 2015 | -2.17x | $-29.79 Million | $13.73 Million | ▼ -846.3% |
| 2014 | -0.23x | $-20.41 Million | $89.02 Million | ▼ -16.6% |
| 2013 | -0.20x | $-16.37 Million | $83.19 Million | ▲ +97.4% |
| 2012 | -7.69x | $-15.58K | $2.03K | — |